Respiratory investigation最新文献

{"title":"Corrigendum to “Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis” [Respir Invest, Volume 62, Issue 3, May 2024, Pages 481–487]","authors":"Yosuke Fukuda , Yoshitaka Uchida , Koichi Ando , Ryo Manabe , Akihiko Tanaka , Hironori Sagara","doi":"10.1016/j.resinv.2025.02.006","DOIUrl":"10.1016/j.resinv.2025.02.006","url":null,"abstract":"","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Page 467"},"PeriodicalIF":2.4,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer","authors":"Naoyuki Nogami ,&nbsp;Shigeki Umemura ,&nbsp;Toshiyuki Kozuki ,&nbsp;Yoshitaka Zenke ,&nbsp;Junko Ohtani ,&nbsp;Mikio Ishii ,&nbsp;Shirong Han ,&nbsp;Kazuo Noguchi ,&nbsp;Hidehito Horinouchi","doi":"10.1016/j.resinv.2025.02.010","DOIUrl":"10.1016/j.resinv.2025.02.010","url":null,"abstract":"<div><h3>Background</h3><div>Part D of the open-label, phase 1 KEYNOTE-011 study (<span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, NCT01840579) evaluated the safety and tolerability, pharmacokinetics, and antitumor activity of pembrolizumab plus ipilimumab as first-line treatment in Japanese participants with advanced NSCLC.</div></div><div><h3>Methods</h3><div>Eligible participants were aged ≥20 years with previously untreated stage IIIB/IV NSCLC (any tumor PD-L1 status permitted). Participants received ≤35 doses of pembrolizumab 200 mg every 3 weeks intravenously (days 1 and 22 of 6-week cycles) plus ≤18 doses of ipilimumab 1 mg/kg every 6 weeks intravenously. The primary endpoint was dose-limiting toxicities (DLTs) occurring during the DLT evaluation period (first 6 weeks of study treatment). The secondary endpoint was pembrolizumab pharmacokinetics; exploratory endpoints included evaluation of antitumor activity. Results were summarized descriptively.</div></div><div><h3>Results</h3><div>All 6 participants enrolled in Part D received ≥1 dose of pembrolizumab plus ipilimumab. No DLTs were observed. AEs of any cause were reported in 5 participants (83%; grade 3–4, n = 2 [33%]). No fatal AEs occurred. Two participants had AEs leading to discontinuation: grade 3 pneumonia (n = 1; not treatment-related) and grade 2 organizing pneumonia (n = 1; treatment-related). The geometric mean (% coefficient of variation) pembrolizumab maximum and minimum serum concentrations were 72.7 μg/mL (10.1%) and 8.3 μg/mL (16.2%), respectively, at cycle 1 and 86.2 μg/mL (3.6%) and 28.1 μg/mL (23.6%), respectively, at cycle 4. Objective response rate was 50% (95% CI, 12%–88%); 3 participants had PR.</div></div><div><h3>Conclusion</h3><div>Pembrolizumab plus ipilimumab had a manageable safety profile and showed antitumor activity in Japanese participants with previously untreated advanced NSCLC.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 296-302"},"PeriodicalIF":2.4,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desaturation after forced vital capacity measurement is suggested diffusing capacity disorder","authors":"Kohei Shimizu ,&nbsp;Naoji Masuya ,&nbsp;Ikue Suzuki ,&nbsp;Tomoya Uchimura ,&nbsp;Nobuaki Sasaki ,&nbsp;Toshinori Uto ,&nbsp;Yui Kawauchi ,&nbsp;Miyabi Watanabe ,&nbsp;Yujiro Takai ,&nbsp;Hidenari Nagai","doi":"10.1016/j.resinv.2025.01.006","DOIUrl":"10.1016/j.resinv.2025.01.006","url":null,"abstract":"<div><h3>Background</h3><div>Monitoring oxygen saturation (SpO2) in pulmonary functional testing (PFT) is useful to check for hypoxemia, especially in patients who performed home oxygen therapy. Although SpO2 is not part of PFT, assessing it allows testing to be performed more safely.</div><div>The relationship between desaturation in the 6MWT and DLCO is known, but that between lower DLCO and mean desaturation in the PFT is unclear.</div></div><div><h3>Methods</h3><div>We performed a retrospective study to investigate the relationship between PFT parameters, SpO2 values, and patient characteristics. From April 2021 to July 2022, data from 311 patients were included in the study (male 210 patients, 67.5%).</div></div><div><h3>Results</h3><div>The parameter most closely correlated with desaturation was %DLCO. Multiple linear regression indicated that HOT, %VC, FEV 1%, and %DLCO were significant predictors of desaturation. The best AUC for the relation of desaturation to %DLCO was for 3% desaturation (cut-off value, 53.0%; sensitivity, 0.691; specificity, 0.780).</div></div><div><h3>Conclusions</h3><div>Results showed that desaturation was one of the significant indicators. Monitoring SpO2 during the FVC measurement might help to identify patients with respiratory diseases and high-level diffusing capacity disorder. SpO2 desaturation might be one indicator of diffusing capacity for the patient who can not measure DLCO single breath method. Therefore, SpO2 might be useful not only for monitoring whether a patient has hypoxemia, but also as a predictor of diffusing capacity.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 289-295"},"PeriodicalIF":2.4,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143463963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Key predictors of long-term survival after lung transplantation in Japan","authors":"Shunta Mukai ,&nbsp;Takashi Hirama ,&nbsp;Ken Onodera ,&nbsp;Tatsuaki Watanabe ,&nbsp;Sadatomo Tasaka ,&nbsp;Yoshinori Okada","doi":"10.1016/j.resinv.2025.02.002","DOIUrl":"10.1016/j.resinv.2025.02.002","url":null,"abstract":"<div><h3>Background</h3><div>Lung transplantation (LTx) is essential for treating end-stage lung diseases in Japan, achieving favorable long-term survival despite donor shortages. However, factors associated with long-term survival after transplantation remain unclear. This study aims to identify key predictors influencing post-transplant outcomes.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on LTx recipients at Tohoku University Hospital from 2000 to 2019, with a follow-up period of five years to 2024. Recipients were categorized into short survivors (&lt;5 years) and long survivors (≥5 years). The analysis focused on recipient demographics, donor characteristics, surgical factors, and post-transplant outcomes.</div></div><div><h3>Results</h3><div>Of 124 recipients, 36 were short survivors, and 88 were long survivors. Long-term survivors were younger, with a lower prevalence of patients aged 55 years and older. Additionally, fewer long-term survivors received lungs from critically marginal donors compared to short-term survivors. CMV serology was a significant factor, with a higher incidence of CMV disease observed in short-term survivors.</div></div><div><h3>Conclusion</h3><div>The study identified younger age, selective donor use, and CMV status as key predictors associated with long-term survival after LTx in Japan. The findings underscore the importance of targeted CMV management strategies and suggest that future multicenter studies with larger, more diverse populations are needed to confirm these results and further enhance long-term survival outcomes.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 265-272"},"PeriodicalIF":2.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidance for type 2 inflammatory biomarkers","authors":"Kazuto Matsunaga ,&nbsp;Akira Koarai ,&nbsp;Hiroshi Koto ,&nbsp;Toshihiro Shirai ,&nbsp;Masato Muraki ,&nbsp;Masao Yamaguchi ,&nbsp;Masayuki Hanaoka","doi":"10.1016/j.resinv.2025.01.003","DOIUrl":"10.1016/j.resinv.2025.01.003","url":null,"abstract":"<div><div>Type 2 inflammation in the airways and lungs is inflammation induced by type 2 cytokines such as IL-4, IL-5, and IL-13, produced primarily by type 2 helper T cells and type 2 innate lymphoid cells, and causes changes in the physiology and structure of the airways. Type 2 inflammation is currently in the spotlight because of its direct link to the treatment of several airway and lung diseases. Abundant evidences have accumulated that inflammatory biomarkers such as blood eosinophils, fractional exhaled nitric oxide, and IgE are essential clinical tools in the diagnosis and management of asthma and COPD. It is well known that asthma and COPD have diverse inflammatory phenotypes even when clinical features are similar, and it has been demonstrated that assessment of airway inflammation with biomarkers can improve diagnostic accuracy, determine safer and more effective treatment strategies, and predict future risks such as exacerbations and lung function decline. The Japanese Respiratory Society has published clinical practice guidelines for the evaluation of type 2 inflammation in the airways and lungs. In addition to asthma and COPD, the guide covers a wide range of airway and lung diseases, including interstitial lung disease, allergic bronchopulmonary mycosis, allergic rhinitis, and eosinophilic chronic rhinosinusitis. It also provides comprehensive guidelines covering a variety of clinical biomarkers. The purpose of this guidance is to provide evidences for the interpretation of type 2 inflammation measurements and to promote the widespread use of inflammation assessment to further improve the efficiency of airway and respiratory disease management.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 273-288"},"PeriodicalIF":2.4,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of serum Krebs von den Lungen-6 and surfactant protein-D levels for the diagnosis of immune checkpoint inhibitor-induced immune-related pneumonitis","authors":"Shogo Nakai ,&nbsp;Masato Karayama ,&nbsp;Yusuke Inoue ,&nbsp;Hideki Yasui ,&nbsp;Hironao Hozumi ,&nbsp;Yuzo Suzuki ,&nbsp;Kazuki Furuhashi ,&nbsp;Tomoyuki Fujisawa ,&nbsp;Noriyuki Enomoto ,&nbsp;Satoshi Funayama ,&nbsp;Shintaro Ichikawa ,&nbsp;Satoshi Goshima ,&nbsp;Naoki Inui ,&nbsp;Takafumi Suda","doi":"10.1016/j.resinv.2025.02.005","DOIUrl":"10.1016/j.resinv.2025.02.005","url":null,"abstract":"<div><h3>Background</h3><div>Immune-related pneumonitis (irP) is a severe immune-related adverse event that can occur after treatment with immune checkpoint inhibitors (ICIs); accurate monitoring and early diagnosis are crucial. Serum Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) are used to diagnose and monitor the disease activity of various types of interstitial lung disease. This study evaluated the usefulness of KL-6 and SP-D for diagnosing irP in cancer patients receiving ICIs.</div></div><div><h3>Patients and methods</h3><div>This retrospective observational study included cancer patients treated with more than two cycles of ICIs from September 2014 to October 2023. Receiver operating characteristic (ROC) analysis was used to assess the diagnostic utility of KL-6 and SP-D.</div></div><div><h3>Results</h3><div>Of the 724 cancer patients, 631 were included in the analysis, and 64 developed irP. The ROC analysis showed that KL-6 and SP-D had areas under the curve of 0.803 and 0.845, respectively. Serum KL-6 ≥ 500 U/mL had a sensitivity of 65.6% and a specificity of 83.4% for the diagnosis of irP, while SP-D ≥ 110 ng/mL had a sensitivity of 66.7% and a specificity of 88.6%. Combining both KL-6 ≥ 500 U/mL and SP-D ≥ 110 ng/mL resulted in a specificity of 96.6%, with a sensitivity of 46.7%. Combining either KL-6 ≥ 500 U/mL or SP-D ≥ 110 ng/mL resulted in a sensitivity of 85.0%, with a specificity of 75.5%. SP-D levels were significantly associated with irP severity, while KL-6 levels were not.</div></div><div><h3>Conclusions</h3><div>Serum KL-6 and SP-D are useful for diagnosing irP in cancer patients receiving ICIs.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 259-264"},"PeriodicalIF":2.4,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143427997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appreciation to reviewers in 2024","authors":"","doi":"10.1016/S2212-5345(25)00015-2","DOIUrl":"10.1016/S2212-5345(25)00015-2","url":null,"abstract":"","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 2","pages":"Pages I-II"},"PeriodicalIF":2.4,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143436634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of taste changes caused by inhalers on adherence to inhalation therapy among patients with asthma and chronic obstructive pulmonary disease","authors":"Takeshi Matsumoto,&nbsp;Yuichi Kajiwara,&nbsp;Tomoya Matoba,&nbsp;Akiko Kaneko,&nbsp;Takahiro Fujiki,&nbsp;Yusuke Kusakabe,&nbsp;Emi Nakayama,&nbsp;Ayaka Tanaka,&nbsp;Naoki Yamamoto,&nbsp;Mayuko Tashima,&nbsp;Chikara Ito,&nbsp;Kensaku Aihara,&nbsp;Shinpachi Yamaoka","doi":"10.1016/j.resinv.2025.02.004","DOIUrl":"10.1016/j.resinv.2025.02.004","url":null,"abstract":"<div><h3>Background</h3><div>Adherence to inhalation therapy impacts treatment outcomes of asthma and chronic obstructive pulmonary disease. Although taste changes induced by inhaled medications may influence adherence, this matter remains underexplored. This study aimed to elucidate the characteristics of taste changes caused by inhaled medications and their association with adherence.</div></div><div><h3>Methods</h3><div>Consecutive patients who regularly visited our hospital from August 2023 to December 2023 were recruited. Sweet, bitter, sour, and salty taste changes were assessed using a visual analog scale. Adherence was measured using a structured questionnaire.</div></div><div><h3>Results</h3><div>Data from 491 inhaler responses (463 patients, aged 68.2 ± 13.5 years) were analyzed. Inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) therapy promoted the most significant bitter taste change. Besides a long duration of taste changes (over a minute), dry powder inhaler devices (β = 0.19, P &lt; 0.001) were significantly associated with sweet taste changes. Younger age (β = −0.17, P &lt; 0.001), absence of a water rinse before inhalation (β = −0.09, P = 0.027), and inhalers containing LAMA (β = 0.22, P &lt; 0.001) were associated with bitter taste changes. Older age (β = 0.10, P = 0.025) was associated with sour taste changes. Bitter taste changes (β = −0.17, P = 0.027) among users of inhalers containing LAMA and younger age (β = 0.15, P = 0.011) among users of inhalers not-containing LAMA were associated with poor adherence.</div></div><div><h3>Conclusions</h3><div>ICS/LABA/LAMA therapy induced the most significant bitter taste changes. The absence of a water rinse before inhalation was associated with bitter taste changes. Bitter taste changes among users of inhalers containing LAMA were correlated with poor adherence, highlighting the need for targeted interventions to improve adherence.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 252-258"},"PeriodicalIF":2.4,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143419938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic chronic rhinosinusitis as a predictor of super-responder and clinical remission in patients with uncontrolled type 2-high severe asthma treated with biologics","authors":"Satoshi Hamada ,&nbsp;Eriko Ogino ,&nbsp;Hirotaka Yasuba","doi":"10.1016/j.resinv.2025.02.003","DOIUrl":"10.1016/j.resinv.2025.02.003","url":null,"abstract":"<div><div>Identifying which biomarkers and comorbidities of type 2 (T2) inflammation to focus on when selecting biologics has remained challenging. We retrospectively examined which biomarkers and comorbidities could influence asthma control among T2-high severe asthma patients receiving biologics. Patients without any maintenance oral corticosteroids and exacerbations requiring systemic corticosteroids indicated super-responder (SR). Clinical remission (CR) was defined as fulfilling the following criteria in addition to achieving SR: asthma symptom improvement (asthma control test score ≥23) and pulmonary function improvement (%forced expiratory volume in 1 s ≥ 80%). We initiated and switched biologics to achieve SR and CR. In total, 111 patients were evaluated, among whom 85.6% and 27.0%–50.5% demonstrated SR and CR, respectively. CR was more frequently observed among patients with severe eosinophilic chronic rhinosinusitis (ECRS) than among those without it. Attention must be paid to the existence of severe ECRS to achieve CR in patients with uncontrolled T2-high severe asthma.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 247-251"},"PeriodicalIF":2.4,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143403309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-minute sit-to-stand test to detect gas exchange capacity during exercise stress in patients with idiopathic or progressive pulmonary fibrosis: A randomized, crossover trial","authors":"Yoshito Miyata,&nbsp;Akihiko Tanaka,&nbsp;Yuiko Goto,&nbsp;Takaya Ebato,&nbsp;Hiromitsu Suganuma,&nbsp;Makoto Nojo,&nbsp;Hatsuko Mikuni,&nbsp;Tomoki Uno,&nbsp;Yoshitaka Uchida,&nbsp;Megumi Jinno,&nbsp;Shin Ohta,&nbsp;Tetsuya Homma,&nbsp;Yoshio Watanabe,&nbsp;Sojiro Kusumoto,&nbsp;Hironori Sagara","doi":"10.1016/j.resinv.2025.01.008","DOIUrl":"10.1016/j.resinv.2025.01.008","url":null,"abstract":"<div><h3>Background</h3><div>The 6-min walk test (6MWT), used to monitor disease progression or exacerbation in interstitial lung disease, faces challenges such as requiring a 30-m walking path and difficulty assessing patients with gait disturbance. The 1-min sit-to-stand test (1STST) offers a convenient alternative, potentially addressing these issues. Despite its advantages, the effectiveness of the 1STST in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) still needs to be explored. We assessed 1STST's ability to detect exercise-induced desaturation in a randomized, crossover trial involving patients with IPF or PPF.</div></div><div><h3>Methods</h3><div>Participants were divided into group A (6MWT to 1STST) and B (1STST to 6MWT), with a 30-min rest period between the tests. The primary endpoint was the difference in nadir oxygen saturation (SpO₂) between the groups throughout the study. Secondary endpoints included the percentage of participants with a nadir SpO₂ &lt;88% during the tests, a decline of ≥4% in SpO_2, and the variation in Borg scores post-tests.</div></div><div><h3>Results</h3><div>Twenty-three participants (91.3% male; mean age ± standard deviation: 77.2 ± 7.4 years) diagnosed with IPF and PPF were enrolled in this study. The difference in nadir SpO₂ between the 1STST and 6MWT was 1.14% (95% confidence interval: −0.18, 2.48), with the 95% confidence intervals falling within the predefined equivalence range. No significant differences were observed in the secondary endpoints.</div></div><div><h3>Conclusions</h3><div>The results suggest that the 1STST is as effective as the 6MWT in detecting desaturation in patients with IPF and PPF.</div></div><div><h3>Trial registration</h3><div>This study was registered on the website of the Japan Registry of Clinical Trials (jRCT1032230037; URL: <span><span>https://jrct.niph.go.jp/</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 241-246"},"PeriodicalIF":2.4,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143379301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}